This study aimed to assess overactive bladder (OAB) treatment patterns and factors associated with effectiveness and persistence.
A prospective, longitudinal, observational registry study of adults starting OAB therapy with mirabegron or antimuscarinics was undertaken. Primary endpoints were time from treatment initiation to discontinuation/switching; proportion who discontinued/switched; and reasons for discontinuation/switching. Secondary endpoints included OAB Symptom Score (OABSS), OAB Questionnaire: Short Form, and OAB Bladder Assessment Tool scores; factors associated with effectiveness and persistence; and safety.
In total, 556 patients initiating mirabegron and 250 initiating antimuscarinics were enrolled. There was no treatment switch, change, or discontinuation in 68.5% of the mirabegron initiator group and median time to treatment change was not reached. Mean initial treatment duration was 130.8 days. In multivariable models, baseline OABSS was the only variable significantly associated with change from baseline in OABSS, and patients with mild and moderate OAB had significantly better persistence with mirabegron than those with severe OAB. Urinary tract infection was the most common adverse event with mirabegron. There was no treatment switch, change, or discontinuation in 60.4% of the antimuscarinics initiator group and median time to treatment change was not reached. Solifenacin was the most frequent initial treatment (66.0%). Mean treatment duration was 122.2 days. In multivariable models, baseline OABSS was the only variable significantly associated with change from baseline in OABSS, while patients with OAB medication in the 12 months before enrollment had significantly better persistence with antimuscarinics than those with no previous OAB medication. Dry mouth was the most common adverse event with antimuscarinics.
Mirabegron and solifenacin were commonly prescribed as first-line OAB medications. There was no treatment switch, change, or discontinuation in more than 60% of the mirabegron initiator and antimuscarinics initiator groups. Mean initial treatment duration was 130.8 days and 122.2 days for mirabegron and antimuscarinics, respectively. Graphical Abstract available for this article.
ClinicalTrials.gov NCT03572231.
Advances in therapy. 2024 Mar 02 [Epub ahead of print]
Seung-June Oh, Sung Tae Cho, Hann-Chorng Kuo, Eric Chieh-Lung Chou, Yu-Chao Hsu, Kyu-Sung Lee, Farid Hadi, Yi Song, Budiwan Sumarsono
Department of Urology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea., Department of Urology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea., Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan., Department of Urology, China Medical University Hospital, Taichung, Taiwan., Department of Urology, Linkou Chang Gung Memorial Hospital, Taipei, Taiwan., Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea. ., Astellas Pharma Medical Affairs, Singapore, Singapore., Astellas Pharma Global Development, Inc., Northbrook, IL, USA.